GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solara Active Pharma Sciences Ltd (BOM:890202) » Definitions » Piotroski F-Score

Solara Active Pharma Sciences (BOM:890202) Piotroski F-Score : 4 (As of Mar. 29, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Solara Active Pharma Sciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solara Active Pharma Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Solara Active Pharma Sciences's Piotroski F-Score or its related term are showing as below:

BOM:890202' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 4   Max: 7
Current: 4

During the past 8 years, the highest Piotroski F-Score of Solara Active Pharma Sciences was 7. The lowest was 4. And the median was 4.


Solara Active Pharma Sciences Piotroski F-Score Historical Data

The historical data trend for Solara Active Pharma Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solara Active Pharma Sciences Piotroski F-Score Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial 5.00 7.00 - 4.00 4.00

Solara Active Pharma Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.00 - - -

Competitive Comparison of Solara Active Pharma Sciences's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solara Active Pharma Sciences's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was ₹-5,674 Mil.
Cash Flow from Operations was ₹1,089 Mil.
Revenue was ₹12,384 Mil.
Gross Profit was ₹3,999 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (28992.8 + 23509.6) / 2 = ₹26251.2 Mil.
Total Assets at the begining of this year (Mar23) was ₹28,993 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,174 Mil.
Total Current Assets was ₹8,008 Mil.
Total Current Liabilities was ₹12,429 Mil.
Net Income was ₹-222 Mil.

Revenue was ₹13,792 Mil.
Gross Profit was ₹5,660 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (29449.6 + 28992.8) / 2 = ₹29221.2 Mil.
Total Assets at the begining of last year (Mar22) was ₹29,450 Mil.
Long-Term Debt & Capital Lease Obligation was ₹2,463 Mil.
Total Current Assets was ₹11,875 Mil.
Total Current Liabilities was ₹11,011 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solara Active Pharma Sciences's current Net Income (TTM) was -5,674. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solara Active Pharma Sciences's current Cash Flow from Operations (TTM) was 1,089. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-5673.9/28992.8
=-0.19570031

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-221.8/29449.6
=-0.00753151

Solara Active Pharma Sciences's return on assets of this year was -0.19570031. Solara Active Pharma Sciences's return on assets of last year was -0.00753151. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Solara Active Pharma Sciences's current Net Income (TTM) was -5,674. Solara Active Pharma Sciences's current Cash Flow from Operations (TTM) was 1,089. ==> 1,089 > -5,674 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=1174.4/26251.2
=0.044737

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=2462.5/29221.2
=0.08427101

Solara Active Pharma Sciences's gearing of this year was 0.044737. Solara Active Pharma Sciences's gearing of last year was 0.08427101. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=8007.5/12428.5
=0.64428531

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=11875.4/11011.3
=1.07847393

Solara Active Pharma Sciences's current ratio of this year was 0.64428531. Solara Active Pharma Sciences's current ratio of last year was 1.07847393. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Solara Active Pharma Sciences's number of shares in issue this year was 39.057. Solara Active Pharma Sciences's number of shares in issue last year was 39.057. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3998.8/12383.9
=0.32290312

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5659.7/13791.9
=0.41036405

Solara Active Pharma Sciences's gross margin of this year was 0.32290312. Solara Active Pharma Sciences's gross margin of last year was 0.41036405. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=12383.9/28992.8
=0.42713708

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=13791.9/29449.6
=0.46832215

Solara Active Pharma Sciences's asset turnover of this year was 0.42713708. Solara Active Pharma Sciences's asset turnover of last year was 0.46832215. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solara Active Pharma Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Solara Active Pharma Sciences  (BOM:890202) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Solara Active Pharma Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Solara Active Pharma Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Solara Active Pharma Sciences Business Description

Traded in Other Exchanges
Address
27, Vandaloor Kelambakkam Road, 2nd Floor. Admin Block, Melakottaiyur (Post), Keelakottaiyur Village, Chennai, TN, IND, 600 127
Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.

Solara Active Pharma Sciences Headlines

No Headlines